The safety of weekly low dose oral methotrexate in an Oriental population with rheumatoid arthritis

Annals of the Academy of Medicine Singapore

Volumn 26, Issue 2, 1997, Pages 205-209

  Thumboo, J ^a   Koh, W H ^a   Leong, K H ^a   Boey, M L ^a   Feng, P H ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

Anti malarials; Asia; Drugs; Infection; Leucopaenia

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; ASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; RASH; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; SAFETY; SINGAPORE;

EID: 0030995598     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Harth M. Gold in rheumatoid arthritis: standard, substitute or sham? J Rheumatol 1993; 20:771-3.
2. Felson D T, Anderson J J, Menon R F. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis: results of two meta-analysis. Arthritis Rheum 1990; 33 1449-61
3. Fries J F, Williams C A, Ramey D, Bloch D A. The relative toxicity of disease modifying anti-rheumatic drugs. Arthritis Rheum 1993; 36:297-306.
4. Wolfe F, Hawley DJ, Cathey M A. Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: a 14 year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17:994-1002.
5. Hochberg M C. Influencing mortality outcomes in RA [editorial]. Bull Rheum Dis 1991; 41-4.
6. Alarcon G A, Tracy I C, Blackburn W D Methotrexate in rheumatoid arthritis: toxic events as the major factor in limiting long term treatment Arthritis Rheum 1989; 32:671-6.
7. Al-awadi A, Dale P, McKendry R J R. Pancytopaenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 1993; 20.1121-5
8. Carroll G J, Thomas R, Phatonros C G, Atchison M H, Leslie A L, Cook N J, et al. Prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994; 21:51-4
9. Chandran G, Ahem M J, Hall P D, Geddes R, Smith M D, Hill W, et al. Cirrhosis of the liver in patients with rheumatoid arthritis receiving low dose methotrexate. Br J Rheumatol 1994; 33:981-4.
10. Flood D A, Chan C K, Pruzanski W. Pneumocystis carinii pneumonia associated with methotrexate therapy in rheumatoid arthritis. J Rheumatol 1991, 18.1254-6.
11. Arnett F C, Edwottey S M, Bloch D A. The Amencan Rheumatism Association 1987 revised criteria for the diagnosis of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
12. McKendry R J R, Dale P. Adverse events of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20:1850-6.
13. Morgan S L, Alarcon G S, Krumdieck C L. Folate administration during methotrexate therapy. it makes sense. J Rheumatol 1993; 20:929-30.
14. Kremer J M. Methotrexate therapy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1989; 15:533-56
15. Schnabel A, Gross W L. Low dose methotrexate in rheumatic diseases - efficacy, side events and risk factors for side effects. Semin Arthritis Rheum 1994; 23:310-27.
16. Furst D E, Erikson N, Clute L, Koehnike R, Burmester L F, Kohler J A Adverse experience with methotrexate during 176 weeks of a long-term prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990; 17:1628-35.
17. Kremer J M, Lee J K. A long term prospective study of the use of methotrexate in rheumatoid arthritis: update at 53 months. Arthritis Rheum 1988; 31:577-84
18. Schnabel A, Herlyn K, Gross W L. Long term tolerability of methotrexate on doses exceeding 15 mg a week in rheumatoid arthritis. Arthritis Rheum 1994; 37(suppl):S254
19. Cohen M G, Li E K, Ng P Y, Chan K L. Extra-articular manifestations are uncommon in southern Chinese with rheumatoid arthritis. J Rheumatol 1993, 32.209-11
20. Boey M L, Tan K T, Lee K S, Fong K Y, Feng P H Patterns of disease in rheumatoid arthritis Singapore Med J 1987; 8:23-7.
21. Engel A, Roberts J, Burch T A. Rheumatoid arthritis in adults. United States 1960-2 Vital and Health Statistics, National Centre for Health Statistics Series 2 No 17. United States DHEW, 1966.
22. Cheung P, editor. Yearbook of Statistics of Singapore. Singapore: Department of Statistics, 1993.32.
23. MacKinnon S K, Starkebaum G, Willkens R F. Pancytopaenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1985; 15:119-26.
24. Kremer J M, Alarcon G D S, Lightfoot Jr R W, Willkens R F, Furst D E, Williams H J, et al. Methotrexate for rheumatoid arthritis - suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37:316-28.
25. Antonelli M A, Moreland L W, Biuli J E. Herpes zoster in patients with rheumatoid arthritis treated with low dose, weekly methotrexate Am J Med 1995; 90:295-8.
26. Day R O, SAARDS-1. In: Klippel J R, Dieppe P A, editors. Rheumatology. London: Mosby Yearbook , 1994:121-9.
27. Fries J F, Singh G, Lenert L, Furst D E. Aspirin, hydroxychloroquine and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33.1611-8.
28. Singh G, Fries J F, William C A, Zartarain E, Spitz P, Black D A. Toxicity profiles of disease modifying anti-rheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18:188-94